Statement of Changes in Beneficial Ownership (4)
January 13 2021 - 6:15PM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden
hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
|
1. Name and Address of Reporting Person
*
PYOTT DAVID E I |
2. Issuer Name and Ticker or Trading Symbol
PLIANT THERAPEUTICS, INC.
[
PLRX
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director _____ 10% Owner
_____ Officer (give title below) _____ Other (specify below)
|
|
(Last)
(First)
(Middle)
C/O PLIANT THERAPEUTICS, INC., 260 LITTLEFIELD AVENUE |
3. Date of Earliest Transaction
(MM/DD/YYYY)
1/12/2021 |
|
(Street)
SOUTH SAN FRANCISCO, CA 94080
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security
(Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code
(Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security
(Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code
(Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) | 8. Price of Derivative Security
(Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
| Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
| Stock Option (right to buy) | $27.71 | 1/12/2021 | | A | | 26573 | | (1) | 1/11/2031 | Common Stock | 26573 | $0.00 | 26573 | D | |
| Explanation of Responses: |
| (1) | 1/36th of the shares subject to such option vest and become exercisable in substantially equal installments on each monthly anniversary of January 12, 2021, subject to the Reporting Person's continuous service to the Issuer on each such date. |
Reporting Owners
|
| Reporting Owner Name / Address | Relationships |
| Director | 10% Owner | Officer | Other |
PYOTT DAVID E I
C/O PLIANT THERAPEUTICS, INC.
260 LITTLEFIELD AVENUE
SOUTH SAN FRANCISCO, CA 94080 | X |
|
|
|
Signatures
|
| /s/ Mike Ouimette, attorney-in-fact | | 1/13/2021 |
| **Signature of Reporting Person | Date |
Pliant Therapeutics (NASDAQ:PLRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Pliant Therapeutics (NASDAQ:PLRX)
Historical Stock Chart
From Apr 2023 to Apr 2024
